What were the key financial results for Xenitra (ASX:XEN) in Q3 2026?

Xenitra reported a preliminary unaudited sales increase of over 300% compared to the previous quarter, with total Q3 revenue reaching $8.3 million. This performance represents a material leap in growth, driven by the company’s expansion into Asian consumer markets.

What specifically caused the 300% sales surge for Xenitra (ASX:XEN)?

The primary catalyst for the revenue spike was Xenitra’s Nutritionals division and a new $30 million strategic partnership with Rockcheck Group to distribute Danone products. This agreement allowed Xenitra to leverage its existing B2B wholesale and e-commerce distribution channels in Asia.

How did Xenitra (ASX:XEN) perform on a month-to-month basis during the third quarter?

The third quarter showed consistent month-on-month acceleration, starting with $1.6 million in sales for January. Revenue climbed to $2.6 million in February before peaking at $4.3 million in March.

What is the business model of Xenitra (ASX:XEN)?

Xenitra operates a blockchain-tokenised sales ecosystem designed to streamline the distribution of fast-moving consumer goods (FMCG), nutraceuticals, and OTC medicines.

What are the main bull points for Xenitra (ASX:XEN) after this news?

The bull case focuses on the massive 300% quarterly growth and the successful execution of the $30 million Rockcheck partnership. Investors may see the $8.3 million quarterly revenue as proof of concept for their blockchain-integrated supply chain.

What are the key risks and bear points for Xenitra (ASX:XEN) investors?

A primary risk is that these figures are "preliminary and unaudited," meaning they could be subject to revision during a formal audit.

Xenitra Q3 sales surge over 300%

Written by Brie CarterPublished Apr. 16 2026Last Updated Apr. 16 2026

Xenitra (ASX:XEN) reported a preliminary unaudited sales increase of over 300% for the third quarter.

The Sydney-based firm, which operates a pioneering blockchain-tokenised sales ecosystem across Asia, saw its Q3 revenue climb to $8.3 million, marking a material leap from the previous quarter’s performance.

The company’s growth trajectory has been particularly robust within the fast-moving consumer goods, nutraceuticals, and over-the-counter medicine sectors.

According to the announcement, this recent surge was primarily fuelled by the Nutritionals division, bolstered by a $30 million partnership with the Rockcheck Group to distribute Danone products.

The expansion leverages Xenitra’s established distribution network, which encompasses B2B wholesale, traditional retail, and major e-commerce platforms throughout the Asian market.

Since 2024, the company has successfully facilitated over $70 million in total sales.

A month-by-month analysis of the Q3 data reveals a consistent upward trend. Sales commenced in January at approximately $1.6 million, grew to over $2.6 million in February, and peaked in March at roughly $4.3 million.

The steady monthly acceleration underscores the successful integration of the Rockcheck partnership and the increasing scalability of Xenitra’s blockchain-integrated supply chain.

At the time of reporting, Xenitra's share price was $0.0040.